PeerView Family Medicine & General Practice CME/CNE/CPE Video Podcast

Go online to PeerView.com/BNB860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. In this animated activity, an expert on homozygous familial hypercholesterolemia (HoFH) discusses the latest data for novel lipid-lowering therapies and offers strategies for individualizing treatment regimens to improve outcomes for patients with HoFH. Upon completion of this activity, participants should be better able to: Apply standards of care to initiate and escalate lipid-lowering therapies in patients with HoFH; Distinguish the therapeutic characteristics of recently approved HoFH therapies according to their mechanisms of action; and Evaluate the benefits and limitations of approved HoFH therapies to individualize patient care.

Go online to PeerView.com/DEC860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. Alzheimer’s disease (AD) is a devastating yet highly prevalent condition, affecting 10% of people aged 65 years and older and increasing in prevalence as the population ages. Recent advances in disease-modifying therapies have allowed for the possibility of reductions in disease progression and improved patient outcomes. Significant advances have also been made in identifying and testing biomarkers for AD that may aid in the early diagnosis of disease, facilitate patient selection for treatment, and monitor therapeutic response. In this activity, based on a recent live event, a panel of expert faculty provide training in the appropriate integration of validated and emerging cerebrospinal fluid (CSF) and plasma biomarkers into the AD diagnostic workup to identify early-stage AD in symptomatic patients. The faculty utilize a case-based approach to model the application and interpretation of fluid biomarkers in clinical practice, as well as highlight advantages and limitations associated with currently available and emerging CSF and plasma biomarkers. Upon completion of this activity, participants should be better able to: Apply validated fluid biomarkers to facilitate a timely neuropathological diagnosis of AD in symptomatic patients; Describe the limitations and advantages associated with currently available and emerging fluid diagnostics; and Integrate emerging plasma biomarkers into the diagnostic workup through appropriate application and accurate interpretation to improve early diagnosis and precision management of AD

Go online to PeerView.com/TGA860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. Eosinophilic esophagitis (EoE) is a chronic allergic type 2 inflammatory disease characterized by a clinical and pathologic phenotype of progressive esophageal dysfunction due to tissue inflammation and fibrosis. Diagnosis of EoE is frequently missed or delayed, which can lead to such complications as esophageal stricture and reduced patient quality of life. Fortunately, targeted biologic therapies already approved for other type 2 inflammatory disorders are approved, or are in development, for the treatment of EoE and appear promising. This case-based activity will offer expert insights for recognizing and diagnosing EoE, monitoring and managing EoE, and integrating targeted therapies into practice. Upon completion of this activity, participants should be better able to: Diagnose eosinophilic esophagitis (EoE) promptly according to the latest guidelines and criteria to decrease the risk of complications precipitated by uncontrolled disease; Apply the latest clinical research developments and updates in treatment guidelines to the management of EoE in collaboration with the healthcare team; and Select treatment, including novel targeted biologic therapies, for patients with EoE based on the latest clinical evidence

Go online to PeerView.com/XMX860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. Psoriasis, a chronic inflammatory disease that affects up to 1 in 20 people worldwide, can drastically impact a patient's quality of life and health. The number of therapies for patients with moderate-to-severe psoriasis has grown steadily over the past 2 decades. Biologic immunotherapies have been the primary agents to gain approval, while small-molecule therapies have lagged in development. Deucravacitinib is a newly approved oral small molecule that inhibits the activity of TYK2, a member of the JAK family. Deucravacitinib allosterically inhibits TYK2 activity by binding to the regulatory domain rather than the catalytic domain. Binding in this way gives deucravacitinib greater specificity for TYK2 versus the closely related JAK1/2/3. Deucravacitinib has demonstrated safety and efficacy in moderate-to-severe chronic plaque psoriasis in two phase 3 pivotal trials (POETYK PSO-1 and PSO-2). Psoriasis Area Severity Index (PASI) 75 and static Physician's Global Assessment (sPGA) 0/1 response rates were significantly higher with deucravacitinib versus placebo or apremilast. In this activity, based on a recent live symposium, expert faculty discuss the clinical implications of targeting TYK2 in psoriasis, as well as strategies to identify patients for whom inhibition of TYK2 would be an appropriate treatment option based on available data. In addition, the faculty delve into the importance of shared decision-making in formulating personalized management plans for patients with psoriasis. Upon completion of this activity, participants should be better able to: Describe the pathophysiology of moderate-to-severe psoriasis as it relates to selective targeting of TYK2; Identify patients with psoriasis for whom inhibition of TYK2 would be an appropriate treatment option based on available efficacy and safety data and practice guidelines; and Develop personalized management plans for patients with psoriasis using principles and tools of shared decision-making, empowering patients to participate in treatment decisions and remain adherent to therapies

Go online to PeerView.com/SRU860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. Despite the availability of testing, vaccines, and treatments, COVID-19 remains a threat—no one can predict when a new strain might surface and many questions remain. The virus that causes COVID-19 is designated severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) and the clinical spectrum of SARS-CoV-2 infection ranges from asymptomatic to critical and fatal illness. Most symptomatic infections are mild; however, a significant number of patients have severe disease requiring hospitalization. Hospitalization and death are more likely in high-risk populations, including older people, individuals with underlying medical problems, and those affected by systemic health and social inequities (ie, minorities, immigrant populations, people of low socioeconomic status, and the disabled). Therapies such as antiviral agents and monoclonal antibodies are available in the United States and Europe for the treatment of COVID-19; however, there are challenges with determining which hospitalized patients may be best suited for which treatment. In this activity, based on a recent live web broadcast, a panel of experts explores strategies to improve outcomes for COVID-19 in the hospital setting, with a focus on designing individualized treatment plans based on current guidelines, evolving evidence, and patient-specific factors. The panel also discusses how differences in drug access and treatment protocols impact the healthcare team in regards to providing individualized treatment programs for patients hospitalized with COVID-19. Upon completion of this activity, participants should be better able to: Assess patients with COVID-19 to make appropriate treatment recommendations based on disease severity; Differentiate therapies for COVID-19 based on the latest safety and efficacy data from clinical trials; Collaborate with the healthcare team to design timely and individualized treatment plans for hospitalized patients with COVID-19 disease based on current guidelines, evolving evidence, and patient-specific factors; and Discuss the clinical implications of prolonged/persistent viral replication in severe COVID-19

Go online to PeerView.com/GAZ860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. In this activity, an expert in neurology discusses strategies for optimizing the biomarker-based diagnosis of Alzheimer’s disease early in the disease course and the selection of appropriate patients who might benefit from novel disease-modifying therapies, as well as a comprehensive care model for the multidisciplinary management of patients with Alzheimer’s disease. Upon completion of this activity, participants should be better able to: Apply current and emerging diagnostic tools to optimize the biomarker-based diagnosis of AD early in the disease course; Select appropriate patients with AD who may benefit from novel disease-modifying therapies based on an understanding of their mechanisms of action, efficacy, and safety profiles; and Utilize a comprehensive care model to optimize the multidisciplinary management of patients with AD

Go online to PeerView.com/DNP860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. What are your skills in managing tenosynovial giant cell tumors (TGCT)—particularly in light of updated phase 3 evidence supporting systemic treatment? Find out in this final part of an educational series on TGCT, where an expert in the field reviews current standards of care and provides updates from a major clinical trial that supports the use of targeted options in conjunction with established multimodal treatment protocols for TGCT management. Upon completion of this activity, participants should be better able to: Apply clinical evidence for the use of targeted options as part of the multimodal management of TGCT, including for patients where continued surgery is unlikely to produce clinical benefits; and Manage safety and dosing considerations with targeted agents in the setting of TGCT.

Go online to PeerView.com/BEN860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. The benefits of prophylaxis with emerging nonfactor therapies in hemophilia have been well-documented, yet despite this clear evidence, many barriers have slowed the integration of effective preventative states in hemophilia A and B. This activity will provide learners with expert insight on new developments with nonfactor prophylaxis in patients with hemophilia A and B, including data from the most recent American Society of Hematology Annual Meeting. Watch an expert-led examination of the evidence supporting novel and emerging nonfactor therapeutics, and hear guidance on implications for real-world practice. Upon completion of this activity, participants should be better able to: Identify barriers and challenges to optimal hemophilia care, including those associated with the use of conventional care options; Evaluate the latest safety/efficacy data supporting the use of novel, emerging nonfactor therapeutics to help guide treatment decisions; Integrate personalized regimens with novel, emerging antibody and siRNA platforms to optimize prophylactic management of hemophilia; and Develop strategies to address practical aspects of hemophilia care associated with the use of novel, emerging nonfactor therapies, including appropriate laboratory monitoring, patient education, adherence counseling, and safety considerations

Go online to PeerView.com/TCG860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. Patients who have severe asthma with uncontrolled symptoms and exacerbations are at risk of losing lung function over time. Research and treatment over the past several years have focused on the downstream effectors of allergic and eosinophilic inflammation, including IgE, sputum and blood eosinophils, and IL-4, IL-5, and IL-13. However, the immunology of the epithelial alarmin TSLP provides an opportunity for a novel approach to treat asthma inflammation. In this activity, based on a recent live symposium, experts apply evidence-based guidelines and translate new data to treat their patients with severe asthma effectively, with a goal of reducing and preventing disease progression (eg, airway remodeling) and preserving quality of life. Upon completion of this activity, participants should be better able to: Explain the rationale for targeting the airway epithelium in the treatment of severe, uncontrolled asthma; Apply recent pathophysiologic insights into the role of epithelial alarmins to the treatment of patients with severe, uncontrolled asthma; and Select individualized treatment for patients with severe, uncontrolled asthma based on various factors, including the latest clinical evidence, without dependency on biomarker status

Go online to PeerView.com/EQC860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. The simultaneous detection of multiple cancers with high specificity via novel blood-based tests has potentially made “universal cancer screening" a goal within reach of many clinicians. As an OB/GYN and/or frontline care provider, are you prepared for this new world of cancer screening? Find out by viewing this CME/MOC video activity, where an expert panel offers case-based perspectives on blood-based cancer screening tools as a complement to current screening methodologies, and what the emergence of multi-cancer early detection tests (MCEDs) means for OB/GYN practice. Watch this video today to gain practical insights on cancer screening in OB/GYN patient care and earn a CME/MOC credit. Upon completion of this activity, participants should be better able to: Assess the scientific basis and clinical utility of multi-cancer early detection (MCED) testing in OB/GYN practice, including available evidence on sensitivity, specificity, and tumor localization accuracy, as well as anticipated impacts on cancer outcomes; Develop strategies to appropriately integrate MCED testing into routine OB/GYN practice, based on a thorough understanding of how, in whom, and when these tests should be used; Update clinical practice workflows to optimize and streamline the follow-up of abnormal cancer screening results, including the implementation of processes to ensure timely referrals to oncology specialists; and Apply best practices to improve patient utilization of cancer screening services (both conventional and MCED-based), including the delivery of effective patient education/counseling and engagement in shared decision-making